Somatic Cell Reprogramming to Glial Cells for CNS Myelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating multiple sclerosis and other neurodegenerative diseases face challenges in generating sufficient glial cells for cell-based therapies, particularly due to immunological incompatibility and logistical impediments in producing oligodendrocyte progenitor cells, which are essential for CNS myelination and remyelination.
Innovation Solution
The method involves reprogramming differentiated somatic cells into glial cells using specific reprogramming factors such as Sox10, Nkx6.2, and Olig2, delivered via vectors like lentiviral vectors, and subsequent sorting to enrich the glial cell population, allowing for the production of functionally equivalent glial cells that can be used in therapies and research.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If embryonic stem cells are used to generate glial cells, then sufficient quantities of glial cells can be produced, but immune rejection occurs due to immunological incompatibility
Solution Approach 1:
The patent uses somatic cell nuclear transfer to create cloned embryonic stem cells that are genetically identical to the patient's somatic cells. This copying approach produces glial cells with the patient's own genetic profile, ensuring immune compatibility while maintaining the ability to generate sufficient quantities of cells for therapy
Solution Approach 2:
The patent changes the genetic parameters of the embryonic stem cells by introducing patient-specific somatic cell nuclei, transforming them from immunologically incompatible donor cells to immunologically compatible patient-specific cells. This parameter change resolves the immune rejection issue while preserving cell production capacity
2Reliability
If somatic cell nuclear transfer is used to create customized stem cells, then immune compatibility is achieved, but technical and logistical impediments complicate the procedure
Solution Approach 1:
The patent extracts the nucleus from patient-specific somatic cells and transfers it into enucleated oocytes, separating the genetic material transfer step from other procedural steps. This extraction approach simplifies the overall process by focusing on the critical nuclear transfer event while reducing logistical complexity
Solution Approach 2:
The patent segments the cell production process into distinct stages: somatic cell nucleus extraction, oocyte enucleation, nuclear transfer, and subsequent glial cell differentiation. This segmentation allows each step to be optimized independently, reducing overall procedural complexity while maintaining immune compatibility
3Reliability
If oligodendrocyte progenitors are expected to mature after myelin damage, then myelin repair should occur, but the progenitors fail to mature resulting in inadequate repair
Solution Approach 1:
The patent performs preliminary differentiation of cloned embryonic stem cells into oligodendrocyte progenitor cells before transplantation. This preliminary action ensures that the transplanted cells are pre-commit to the oligodendrocyte lineage and have enhanced capacity to mature and repair myelin, addressing the failure of endogenous progenitors to mature efficiently
Data Source
AI summary
The present invention relates to the reprogramming of differentiated somatic cells, such as those differentiated cells that arise from embryonic mesoderm, into glial cells. Glial cells produced from this reprogramming are functionally equivalent to glial cells that arise from ectodermal origins.